Clinical and economic outcomes associated with upfront comprehensive genomic profiling in newly diagnosed advanced lung cancer in the United States from 2018-2020: Evidence from the SEQUENCE study.

Authors

Gboyega Adeboyeje

Merck & Co., Kenilworth, NJ

Gboyega Adeboyeje , Eleanor Caplan , Yihua Xu , Monica Chase , Nicole Myer , Sheetal Sheth , Brandon T Suehs

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Genomic testing among patients (pts) with newly diagnosed advanced non-small cell lung cancer (aNSCLC) in the United States: A contemporary clinical practice patterns study.

First Author: Adam Gondos

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Association between real-world, upfront, next-generation sequencing and overall survival (OS) in advanced non–small-cell lung cancer (aNSCLC) in the United States.

First Author: Benjamin Philip Levy

insert_chart_outlined

Poster

2022 ASCO Quality Care Symposium

bookmark_border

Defining key care events to integrate biomarker testing in the workup for patients with advanced non–small cell lung cancer (aNSCLC).

First Author: Nikki A. Martin

insert_chart_outlined

Poster

2022 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Genomic landscape in small intestine cancer from real-world data (RWD) of clinical genomic testing.

First Author: Hiroyuki Takeda